Stock listing
Frankfurt:96X FluoGuide A/S Aktie
German listing (Frankfurt) of FluoGuide A/S · home listing Stockholm:FLUO
Follow FluoGuide A/S into a list and get an email when it puts out news.
Share price · FWB:96X
€2.45 EUR -0.08 (-3.2%)
Close on Nov 20, 2026
- Day range
- €2.45 – €2.48 EURNov 20, 2026
- Market cap
- €40.06M EURAt the close on Nov 20, 2026 · price × 16.35M shares outstanding
- 52-week range
- €2.45 – €4.19 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:FLUO · Home | 29.50 SEK | -2.10 (-6.6%) | 7,913 | 29.60 | 29.90 | 29.00 | 31.60 | Close on Nov 20, 2026 |
| Frankfurt:96X | €2.45 EUR | -0.08 (-3.2%) | — | €2.47 | €2.48 | €2.45 | €2.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:96X · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €2.56 | -0.036 | -1.4% | €2.561 | €2.562 | €2.559 | 0 | |
| €2.596 | +0.006 | +0.2% | €2.688 | €2.688 | €2.594 | 0 | |
| €2.59 | +0.046 | +1.8% | €2.59 | €2.59 | €2.59 | 0 | |
| €2.544 | -0.103 | -3.9% | €2.554 | €2.576 | €2.528 | 0 | |
| €2.647 | +0.011 | +0.4% | €2.642 | €2.662 | €2.626 | 0 | |
| €2.636 | +0.059 | +2.3% | €2.646 | €2.65 | €2.623 | 0 | |
| €2.577 | -0.069 | -2.6% | €2.576 | €2.597 | €2.545 | 0 | |
| €2.646 | +0.104 | +4.1% | €2.62 | €2.652 | €2.595 | 0 | |
| €2.542 | +0.025 | +1.0% | €2.572 | €2.578 | €2.535 | 0 | |
| €2.517 | -0.09 | -3.5% | €2.556 | €2.562 | €2.508 | 0 | |
| €2.607 | -0.008 | -0.3% | €2.606 | €2.609 | €2.605 | 0 | |
| €2.615 | +0.057 | +2.2% | €2.615 | €2.693 | €2.613 | 0 | |
| €2.558 | -0.022 | -0.9% | €2.525 | €2.562 | €2.525 | 0 | |
| €2.58 | +0.011 | +0.4% | €2.532 | €2.582 | €2.49 | 0 | |
| €2.569 | +0.005 | +0.2% | €2.528 | €2.57 | €2.526 | 0 | |
| €2.564 | -0.025 | -1.0% | €2.548 | €2.568 | €2.531 | 0 | |
| €2.589 | -0.032 | -1.2% | €2.589 | €2.603 | €2.587 | 0 | |
| €2.621 | -0.019 | -0.7% | €2.631 | €2.675 | €2.59 | 0 | |
| €2.64 | +0.002 | +0.1% | €2.626 | €2.642 | €2.624 | 0 | |
| €2.638 | -0.018 | -0.7% | €2.644 | €2.653 | €2.638 | 0 | |
| €2.656 | -0.12 | -4.3% | €2.748 | €2.749 | €2.637 | 0 | |
| €2.776 | -0.011 | -0.4% | €2.784 | €2.786 | €2.765 | 0 | |
| €2.787 | +0.017 | +0.6% | €2.807 | €2.816 | €2.666 | 0 | |
| €2.77 | -0.086 | -3.0% | €2.887 | €2.943 | €2.737 | 0 | |
| €2.856 | +0.084 | +3.0% | €2.765 | €2.859 | €2.699 | 0 | |
| €2.772 | +0.011 | +0.4% | €2.717 | €2.773 | €2.703 | 0 | |
| €2.761 | -0.056 | -2.0% | €2.774 | €2.791 | €2.761 | 0 | |
| €2.817 | +0.035 | +1.3% | €2.798 | €2.841 | €2.789 | 0 | |
| €2.782 | -0.003 | -0.1% | €2.771 | €2.783 | €2.706 | 0 | |
| €2.785 | -0.054 | -1.9% | €2.848 | €2.857 | €2.759 | 0 | |
| €2.839 | +0.119 | +4.4% | €2.832 | €2.871 | €2.795 | 0 | |
| €2.72 | -0.025 | -0.9% | €2.717 | €2.739 | €2.717 | 0 | |
| €2.745 | -0.031 | -1.1% | €2.739 | €2.789 | €2.711 | 0 | |
| €2.776 | +0.016 | +0.6% | €2.776 | €2.776 | €2.776 | 0 | |
| €2.76 | -0.107 | -3.7% | €2.76 | €2.76 | €2.76 | 0 | |
| €2.867 | +0.093 | +3.4% | €2.835 | €2.883 | €2.83 | 0 | |
| €2.774 | -0.025 | -0.9% | €2.774 | €2.774 | €2.774 | 0 | |
| €2.799 | -0.011 | -0.4% | €2.733 | €2.816 | €2.732 | 0 | |
| €2.81 | -0.015 | -0.5% | €2.812 | €2.812 | €2.784 | 0 | |
| €2.825 | -0.063 | -2.2% | €2.931 | €2.951 | €2.812 | 0 | |
| €2.888 | -0.002 | -0.1% | €2.919 | €2.935 | €2.869 | 0 | |
| €2.89 | -0.039 | -1.3% | €2.872 | €2.918 | €2.865 | 0 | |
| €2.929 | -0.084 | -2.8% | €3.047 | €3.07 | €2.924 | 0 | |
| €3.013 | +0.098 | +3.4% | €2.948 | €3.051 | €2.938 | 0 | |
| €2.915 | -0.079 | -2.6% | €2.739 | €2.925 | €2.714 | 0 | |
| €2.994 | -0.071 | -2.3% | €2.992 | €2.999 | €2.985 | 0 | |
| €3.065 | +0.143 | +4.9% | €3.022 | €3.078 | €3.019 | 0 | |
| €2.922 | +0.037 | +1.3% | €2.881 | €2.958 | €2.876 | 0 | |
| €2.885 | -0.051 | -1.7% | €2.697 | €2.896 | €2.696 | 0 | |
| €2.936 | -0.028 | -0.9% | €2.831 | €2.954 | €2.83 | 0 | |
| €2.964 | +0.178 | +6.4% | €2.817 | €2.99 | €2.814 | 0 | |
| €2.786 | +0.093 | +3.5% | €2.681 | €2.797 | €2.675 | 0 | |
| €2.693 | +0.028 | +1.1% | €2.692 | €2.693 | €2.68 | 0 | |
| €2.665 | -0.062 | -2.3% | €2.608 | €2.741 | €2.60 | 0 | |
| €2.727 | 0.00 | 0.0% | €2.727 | €2.727 | €2.727 | 0 | |
| €2.727 | +0.013 | +0.5% | €2.727 | €2.727 | €2.727 | 0 | |
| €2.714 | -0.008 | -0.3% | €2.714 | €2.714 | €2.714 | 0 |
- Ticker
- Frankfurt:96X
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Oct 5, 2026
FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma
Latest deck · Jan 21, 2026
Investor Presentation (January 2026)
Investor deck · 11 slides
Latest news
FluoGuide Enrolls First Patient in U.S. Phase 2 Trial of FG001 in High-Grade Glioma
Oct 5, 2026
Closed €2.86 (+3.0%) on Oct 5, 2026
FluoGuide Enters Collaboration with Leica Microsystems, a World Leading Medical Technology Company
Oct 2, 2026
Closed €2.86 (+3.0%) on Oct 5, 2026
FluoGuide A/S publishes interim report for Q2 2026
Aug 25, 2026
Closed €2.67 (-2.3%) on Aug 25, 2026
Invitation to FluoGuide A/S live webcast on 25 August 2026
Aug 12, 2026
Closed €2.65 (-0.3%) on Aug 12, 2026
FluoGuide A/S publishes interim report for Q1 2026
May 27, 2026
Closed €3.56 (-3.7%) on May 27, 2026
Invitation to FluoGuide A/S live webcast on 27 May 2026
May 13, 2026
Closed €3.74 (+1.9%) on May 13, 2026
FluoGuide Receives FDA Fast Track Designation for FG001 in High-Grade Glioma
Mar 18, 2026
Closed €3.23 (+14.7%) on Mar 19, 2026
Notice of Annual General Meeting in FluoGuide A/S
Mar 10, 2026
Closed €2.81 (-3.3%) on Mar 11, 2026
FluoGuide A/S Publishes Annual Report For The Fiscal Year 2025
Feb 25, 2026
Closed €3.09 (-1.8%) on Feb 25, 2026
FluoGuide A/S Publishes Interim Report For Q4 2025
Feb 25, 2026
Closed €3.09 (-1.8%) on Feb 25, 2026
FluoGuide A/S on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 28 in all · newest Oct 5, 2026 · oldest 2025
- Decks
- 5 decks · latest Jan 21, 2026
Where FluoGuide A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:FLUO · Home listing | Stockholm | Sweden | SEK |
| Frankfurt:96X · This page | Frankfurt | Germany | EUR |
Valuation
EV/sales 5,549× against a median of 5.9×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 448.8M SEK
- P/E
- Loss
- EV/sales
- 5,549×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 10.5×
- Gross margin
- −772.1%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.9×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| FluoGuide A/S · OMXSTO:FLUO | US$47.27M | US$43.98M | n/a | 5,549× | n/a | 10.5× | n/a | 0.9× | n/a |
| SYNTHAVERSE Spolka Akcyjna · GPW:SVE | US$48.64M | US$70.93M | n/a | 5.9× | n/a | 1.7× | −43.1% | 0.8× | n/a |
| Heron Therapeutics, Inc. · NASDAQ:HRTX | US$48.04M | US$156.3M | n/a | 1.1× | n/a | 9.8× | −14.5% | 26.8× | 1.93 |
| Helix BioPharma Corp. · TSX:HBP | US$47.94M | US$50.27M | n/a | n/a | n/a | 4.8× | n/a | 0.3× | 0.36 |
| Oncolytics Biotech Inc. · NASDAQ:ONCY | US$47.66M | US$45.23M | n/a | n/a | n/a | n/a | n/a | n/a | 1.27 |
| THX Pharma · EURONEXT:ALTHX | US$47.21M | US$30.91M | n/a | n/a | n/a | 14.5× | n/a | 0.9× | n/a |
| Rafael Holdings, Inc. · NYSE:RFL | US$47.10M | US$25.00M | n/a | 28.6× | n/a | 0.7× | n/a | 0.0× | 0.92 |
| Bio-fd&c Co. Ltd · KRX:251120 | US$46.46M | US$5.26M | 9.8× | 0.4× | 0.9× | 0.9× | 32.8% | 0.0× | n/a |
| Andros Pharmaceuticals Co., Ltd. · TPEX:6917 | US$46.02M | US$35.89M | n/a | 213× | n/a | 3.1× | −969.3% | 0.0× | n/a |
| Werewolf Therapeutics, Inc. · NASDAQ:HOWL | US$46.01M | US$4.14M | n/a | n/a | n/a | 6.8× | n/a | 0.0× | 1.55 |
| MegaPro Biomedical Co., Ltd. · TPEX:6827 | US$45.96M | US$43.30M | n/a | n/a | n/a | 7.0× | n/a | 0.0× | n/a |
| Median of the others | US$47.16M | US$39.59M | 9.8× | 5.9× | 0.9× | 4.8× | −28.8% | 0.0× | 1.27 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 54.11 SEK · Analysts' mean
- EPS, year to Dec 2026
- -3.93 · 1 analyst
- Revenue, year to Dec 2026
- 110K · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Morten Albrechtsen | Chief Executive Officer (CEO) |
| Ole Larsen | Chief Financial Officer (CFO) |
| Donna Haire | Chief Operating Officer |
| Andreas Kjaer | Chief Scientific Officer (CSO) |
Board
| Director | Role |
|---|---|
| Peter Mørch Eriksen | Chairman of the board |
| Andreas Kjaer | Chief Scientific Officer (CSO) |
| Camilla Harder Hartvig | Member of the board |
| Kim Domela Kjøller | Member of the board |
| Mats Thorèn | Vice chairman of the board |
| Michael Engsig | Member of the board |
Events
- Next results
- Nov 26, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 25, 2026 · After close | −7.2% |
| Q1 2026 | May 27, 2026 · After close | +2.8% |
| Q4 2025 | Feb 25, 2026 · Before open | 0.0% |
| Q3 2025 | Nov 27, 2025 · Before open | −1.9% |
| Q2 2025 | Aug 28, 2025 · Before open | +3.8% |
| Q1 2025 | May 28, 2025 · Before open | −2.8% |
| Q4 2024 | Feb 27, 2025 · Before open | −4.4% |
| Q3 2024 | Nov 27, 2024 · Before open | +2.9% |
| Q2 2024 | Aug 29, 2024 · Before open | −1.2% |
| Q1 2024 | May 30, 2024 · Before open | −1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 28, 2024 · Before open | −5.2% |
| Q3 2023 | Nov 29, 2023 · Before open | −3.8% |
| Q2 2023 | Aug 30, 2023 · Before open | +1.1% |
| Q1 2023 | May 31, 2023 · Before open | −1.4% |
| Q4 2022 | Feb 28, 2023 · Before open | +1.7% |
| Q3 2022 | Nov 24, 2022 · Before open | −0.5% |
| Q2 2022 | Aug 25, 2022 · Before open | −2.0% |
| Q1 2022 | May 31, 2022 · Before open | +0.6% |
| Q4 2021 | Mar 30, 2022 · Before open | +1.3% |
| Q3 2021 | Nov 15, 2021 · Before open | +0.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 11 slides | Jan 21, 2026 |
| Investor Presentation (January 2024) | Investor deck | 51 slides | January 2024 |
| Investor Presentation (February 2023) | Investor deck | 43 slides | February 2023 |
| Investor Presentation (November 2022) | Investor deck | 29 slides | November 2022 |
| IPO Roadshow (March 2019) | IPO roadshow | 20 slides | March 2019 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Private placement of shares Closed: SEK 104M raised · SEK 38 a share · Navia Corporate Finance AB +4 Dealers: Navia Corporate Finance AB (co-lead), Redeye AB (co-lead), Translution Capital (co-lead), Navia Corporate Finance (co-lead), Redeye (co-lead) Buyers: Several of the Company's major and institutional shareholders (expressed interest in participating with approximately SEK 95 million) Use of proceeds: Phase II trials of FG001 in HGG in the US and in head and neck cancer, CMC and drug manufacturing for phase III HGG trial, and general corporate purposes | Nov 3, 2025 | US$10.96M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in DKK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 385.0K | 423.0K | 6.51M | 9.61M | 0 | ||
| Cost of revenue | 571.2K | |||||||
| Gross profit | -571.2K | 385.0K | 423.0K | 6.51M | 9.61M | |||
| Research and development | 18.9M | |||||||
| Selling, general and administrative | 24.1M | 20.6M | 20.6M | 8.88M | ||||
| Operating income | -41.0M | -32.6M | -43.7M | -32.2M | -28.8M | -22.2M | -10.7M | -56.7K |
| Depreciation and amortization | 571.2K | 456.0K | 265.0K | 251.0K | 158.0K | 119.0K | 10.6M | 56.7K |
| EBITDA | -40.4M | -32.1M | -43.4M | -32.0M | -28.7M | -22.0M | -97.0K | 0 |
| Interest expense | 4.50M | 86.0K | 43.0K | 175.0K | 216.0K | 51.0K | 965.0K | 0 |
| Income before tax | -46.0M | -34.5M | -43.9M | -32.8M | -29.3M | -22.2M | -11.7M | -57.8K |
| Income tax | -5.63M | -5.50M | -5.50M | -5.50M | -5.50M | -4.73M | -2.05M | -1.09K |
| Net income | -40.4M | -29.0M | -38.4M | -27.3M | -23.8M | -17.5M | -9.65M | -57.8K |
| Earnings per share, basic | -2.87 | -2.23 | -3.22 | -2.33 | -2.15 | -1.78 | -1.49 | -0.09 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 48.8M | 18.6M | 21.7M | 26.0M | 46.8M | 10.6M | 2.34M | 59.0K |
| Short-term investments | 30.0M | 200 | ||||||
| Receivables | 5.93M | 446.0K | 915.0K | 3.36M | 566.0K | 554.0K | 2.38M | |
| Current assets | 86.8M | 26.5M | 28.3M | 34.9M | 52.8M | 16.1M | 4.85M | 75.0K |
| Property, plant and equipment | 53.0K | 211.0K | ||||||
| Total assets | 88.3M | 28.4M | 29.6M | 35.6M | 53.3M | 16.7M | 5.24M | 75.0K |
| Accounts payable | 2.68M | 2.38M | 4.09M | 1.60M | 6.83M | 2.69M | 489.0K | 13.0K |
| Current liabilities | 5.73M | 4.92M | 16.3M | 3.65M | 14.6M | 12.3M | 696.0K | 68.0K |
| Long-term debt | 27.6M | 0 | ||||||
| Total debt | 28.3M | 624.0K | 10.8M | 205.0K | 57.0K | 218.0K | ||
| Total liabilities | 33.8M | 5.31M | 16.9M | 3.65M | 14.6M | 12.3M | 696.0K | 68.0K |
| Shareholders' equity | 54.6M | 23.1M | 12.7M | 32.0M | 38.7M | 4.41M | 4.54M | 7.00K |
| Shares outstanding | 14.1M | 13.0M | 11.9M | 11.7M | 11.0M | 9.80M | 6.48M | 675.3K |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -37.8M | -29.2M | -31.8M | -37.6M | -15.1M | -8.85M | -10.6M | -1.09K |
| Capital spending | 0 | -850.0K | 0 | -64.0K | 0 | 0 | -378.0K | 0 |
| Free cash flow | -37.8M | -30.0M | -31.8M | -37.7M | -15.1M | -8.85M | -10.9M | -1.09K |
| Cash from investing | -30.6M | -987.0K | -37.0K | -117.0K | -42.0K | -390.0K | -390.0K | |
| Cash from financing | 99.3M | 27.1M | 27.5M | 17.0M | 51.2M | 17.2M | 13.2M | 65.5K |
| Change in cash | 29.1M | -3.06M | -4.34M | -20.7M | 36.1M | 8.29M | 2.29M | 64.4K |
Cap table
Built by 6ix from FluoGuide A/S’ releases · as of Nov 3, 2025
- Common shares
- 16,349,313
- Fully diluted
- 16,349,313
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 16,349,313 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 16,349,313 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Andreas Kjaer | Chief Scientific Officer (CSO) · Since at least Nov 5, 2026 |
| Camilla Harder Hartvig | Member of the board · Since at least Mar 10, 2026 |
| Donna Haire | Chief Operating Officer · Since at least Mar 18, 2026 |
| Kim Domela Kjøller | Member of the board · Since at least Mar 10, 2026 |
| Mats Thorèn | Vice chairman of the board · Since at least Mar 10, 2026 |
| Michael Engsig | Member of the board · Since at least Mar 10, 2026 |
| Morten Albrechtsen | Chief Executive Officer (CEO) · Since at least Oct 5, 2026 |
| Ole Larsen | Chief Financial Officer (CFO) · Since at least Aug 25, 2026 |
| Peter Mørch Eriksen | Chairman of the board · Since at least Mar 10, 2026 |
Log in to ask 6ix AI your own questions about FluoGuide A/S.